The results revealed that high LINC01296 expression was significantly related to larger tumour size (OR 3.42, 95% CI 2.08 to 5.63), lymph node metastasis (OR 3.03, 95% CI 2.01 to 4.57) and advanced tumor-node-metastasis (TNM) stage (OR 4.41, 95% CI 2.65 to 7.34).
LINC01296 was enhanced in PDAC tissues and cell lines, and this overexpression was correlated with advanced tumor stages and positive lymph node metastasis in patients with PDAC.
The expression of LINC01296 was significantly higher in most cancer tissues than that in adjacent normal tissues, and was positively correlated with clinical stages of the cancer (<i>P</i>=0.016), lymph node metastasis (<i>P</i>=0.034), and pathologic grades (<i>P</i>=0.012).
LINC01296 expression was correlated with preoperative prostate specific antigen (<i>P</i>=0.002), lymph-node metastasis (<i>P</i>=0.035), Gleason score (<i>P</i><0.001), and tumor stage (<i>P</i>=0.036).